Market Overview:
The global fidaxomicin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of Clostridium difficile infections (CDIs) and rising demand for fidaxomicin as a treatment option. Fidaxomicin is a macrocyclic antibiotic that is effective against CDIs caused by Clostridium difficile strains that are resistant to other antibiotics. It is available in two formulations, tablet and oral suspension, both of which are administered orally. The global fidaxomicin market can be segmented on the basis of purity into 90% purity and 95% purity segments. The 90% purity segment accounted for the majority share of the global fidaxomicin market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its lower price point as compared with 95% pure fidaxomicin products.
Product Definition:
Fidaxomicin (trade name Dificid) is a macrocyclic antibiotic used to treat Clostridium difficile infections. It is the only drug approved by the FDA for treatment of C. difficile infection that has not been associated with increased risk of death.
Purity:90%:
Purity:90% is a new drug developed by the Swiss company, Roche. It’s an antibiotic used to treat bacterial infections of the urinary tract and female reproductive organs. The drug was approved by the FDA in 2016 for treatment of urinary tract infection (UTI) caused by Escherichia coli and Proteus mirabilis bacteria, which are common causes of women's health issues such as pelvic pain, lower back pain, frequent urination & infertility.
Purity:95%:
Purity:95% is a pharmaceutical grade of Fidaxomicin. It is a white crystalline compound, which has an odor similar to vanilla. It has 95% of the active ingredient as compared to the commercial product. The product can be administered orally and it's half life in blood is around 6 hours.
Application Insights:
The hospital application segment led the global market in 2017. The product is used for the treatment of multidrug-resistant TB, which accounts for a significant share of total TB cases worldwide. Fidaxomicin is also being studied as an alternative to current anti-TB drugs, which have shown limited success in clinical trials due to drug resistance developing against them.
Fidaxomicin has been found to be effective against multiresistant tuberculosis (Mtb) and extensively drug-resistant TB (ARD). In addition, it has also been proven effective against all other forms of tuberculosis including cavitary and miliary infections. However, high manufacturing costs are expected to hamper its penetration rate in this segment over the forecast period.
Regional Analysis:
North America was the largest regional market in 2017 owing to high awareness levels and availability of a wide range of products. The region is expected to maintain its dominance over the forecast period due to increasing healthcare expenditure by governments as well as individuals. Favorable reimbursement policies for patients are also driving the demand for fidaxomicin in this region. For instance, under Medicare Part B, fidaxomicin is covered 100% when used together with other oral antibiotics such as amoxicillin or clarithromycin; however, it should be noted that coverage varies from country to country (U.S.).
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidence rates of infectious diseases coupled with growing geriatric population base especially in Japan and China which will boost product demand further on account of higher susceptibility towards infections caused by multidrug-resistant pathogens such as MRSA and VRE bacteria.
Growth Factors:
- Increasing incidence of C. difficile infections: The increasing incidence of C. difficile infections is one of the key growth drivers for the fidaxomicin market. Fidaxomicin is effective in treating C. difficile infections and hence, its demand is expected to rise in the coming years.
- Rising awareness about fidaxomicin: The rising awareness about fidaxomicin among physicians and patients is another key growth driver for this market. This drug has been proven to be more effective than other antibiotics in treating C. difficile infections and hence, its demand is likely to increase in the coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Fidaxomicin Market Research Report
By Type
Purity:90%, Purity:95%, Others
By Application
Hospital, Retail Pharmacies
By Companies
Astellas, Merck, Optimer Pharmaceuticals, Rochem, Tecoland, BrightGene Bio-Medical Technology, Olon, Livzon Group, Astellas
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Fidaxomicin Market Report Segments:
The global Fidaxomicin market is segmented on the basis of:
Types
Purity:90%, Purity:95%, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas
- Merck
- Optimer Pharmaceuticals
- Rochem
- Tecoland
- BrightGene Bio-Medical Technology
- Olon
- Livzon Group
- Astellas
Highlights of The Fidaxomicin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity:90%
- Purity:95%
- Others
- By Application:
- Hospital
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fidaxomicin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fidaxomicin is a drug used to treat infections caused by bacteria. It works by stopping the growth of the bacteria.
Some of the major players in the fidaxomicin market are Astellas, Merck, Optimer Pharmaceuticals, Rochem, Tecoland, BrightGene Bio-Medical Technology, Olon, Livzon Group, Astellas.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fidaxomicin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fidaxomicin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fidaxomicin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fidaxomicin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fidaxomicin Market Size & Forecast, 2020-2028
4.5.1 Fidaxomicin Market Size and Y-o-Y Growth
4.5.2 Fidaxomicin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Purity:90%
5.2.2 Purity:95%
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fidaxomicin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fidaxomicin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Purity:90%
9.6.2 Purity:95%
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Purity:90%
10.6.2 Purity:95%
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Purity:90%
11.6.2 Purity:95%
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Purity:90%
12.6.2 Purity:95%
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Purity:90%
13.6.2 Purity:95%
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fidaxomicin Market: Competitive Dashboard
14.2 Global Fidaxomicin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas
14.3.2 Merck
14.3.3 Optimer Pharmaceuticals
14.3.4 Rochem
14.3.5 Tecoland
14.3.6 BrightGene Bio-Medical Technology
14.3.7 Olon
14.3.8 Livzon Group
14.3.9 Astellas
